Only portable hair removal laser system with blended wavelengths for all skin phototypes to be launched at the Fall Clinical…
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with…
Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study…
Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy Lugano, Switzerland, October 18, 2022 -…
CHICAGO and FORT WORTH, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing…
NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients…
NORCROSS, Ga., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,…
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics…
Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME…